GenomeDx | GenomeWeb

GenomeDx

Results from a study using the database showed that patients with high expression of a certain gene signature had better outcomes with radiation therapy than without it.

Researchers are using GenomeDx's database to improve understanding of the genomic underpinnings of prostate cancer and advance personalized treatment strategies. 

Launching the new biopsy-based version of Decipher, GenomeDx enters more direct competition with tests offered by Myriad Genetics and Genomic Health.

The firm will provide whole-genome profiling for Cedars-Sinai prostate cancer patients, who will also be tested with the Decipher Prostate Cancer Classifier.

The test is designed to predict prostate cancer aggressiveness and launched in the US in 2013.

The cloud-based Decipher GRID database will hold anonymized genomic data from the company's Decipher test and make it available to participating cancer centers.

The study shows that the genomic test may be able to differentiate between which patients would benefit from adjuvant radiation therapy or which do well with salvage treatment.

GenomeDx has implemented the software at its San Diego laboratory to track information related to the Decipher prostate test. 

Palmetto will cover Decipher, an RNA expression-based assay test that predicts cancer aggressiveness using genomic biomarkers.

NEW YORK (GenomeWeb) – GenomeDx announced today an expansion of its research agreement with the Mayo Clinic to start a validation study for the expanded use of GenomeDx's Decipher Prostate Cancer Classifier.

Pages

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.